Our key finding that antiretroviral therapy has a significant impact on preventing tuberculosis in adults with CD4 counts above 350 cells/μl is consistent with studies from developed countries [95],[96] and will need to be considered by healthcare providers, researchers, policymakers, and people living with HIV when weighing the benefits and risks of initiating antiretroviral therapy above 350 cells/μl. This evidence concerns the gene CD4 and tuberculosis.